Business Context and Reporting Period
This Form 8-K is filed by Bio-Rad Laboratories, Inc. on December 13, 2004. The report addresses two primary events: the announcement of a private offering of senior subordinated notes and the revision of historical financial statements to reflect discontinued operations.
Key Financial Metrics and Capital Structure
- Debt Offering: The Company intends to offer up to $200,000,000 aggregate principal amount of senior subordinated notes in a private offering.
- Discontinued Operations: On May 24, 2004, the Company sold its confocal microscopy product line (Microscopy Line) to Carl Zeiss Jena GMBH for approximately $19.8 million.
- Financial Statement Impact: The reclassification of the Microscopy Line as a discontinued operation has no effect on the Company's reported net income (loss).
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for current revenue, profit, cash flow, or margins; these are referenced in attached exhibits (99.2 through 99.5) but not detailed in the body of this report.
Material Changes Versus Prior Periods
The Company has reissued its consolidated financial statements for the years ended December 31, 2003, 2002, and 2001. These revisions reclassify the results of the Microscopy Line as discontinued operations in accordance with SFAS No. 144. Previously, these results were presented in interim statements for 2004 but not fully restated in the annual historical data until this filing.
Guidance, Outlook, and Risks
- Management Commentary: The filing serves to comply with Regulation FD regarding the debt offering and the restatement of financial data.
- Accounting Risks/Contingencies: The financial statements for the year ended December 31, 2001, are unaudited. They were derived from statements originally audited by Arthur Andersen LLP, which has ceased operations. The 2003 and 2002 statements have been audited by Deloitte & Touche LLP.
- Unusual Items: The sale of the Microscopy Line is the primary unusual item driving the financial restatement.
Investor Verification Checklist
- Verify the final terms and closing date of the $200 million senior subordinated notes offering.
- Review Exhibits 99.2 through 99.5 for the specific numerical impact of the discontinued operations on historical revenue and operating income.
- Confirm the unaudited status of the 2001 financial statements and assess any potential implications of the original auditor (Arthur Andersen) ceasing operations.
- Monitor the integration of the remaining Life Science Division assets following the sale of the Microscopy Line.